WBB Securities analyst Stephen Brozak reiterated a Sell rating on Motif Bio plc (MTFB) today. The company’s shares opened today at $2.80, close to its 52-week low of $2.61.
Brozak wrote:
“We have not seen the CRL and therefore cannot comment on the specific steps that will be required to meet its terms. We are therefore reiterating our Sell Rating of MTFB at this time.”
According to TipRanks.com, Brozak is a 4-star analyst with an average return of 12.5% and a 46.4% success rate. Brozak covers the Healthcare sector, focusing on stocks such as RedHill Biopharma, ADMA Biologics, and SCYNEXIS.
The the analyst consensus on Motif Bio plc is currently a Moderate Sell rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.50 and a one-year low of $2.61. Currently, Motif Bio plc has an average volume of 4,293.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motif Bio Plc is a clinical stage biopharmaceutical company which develops novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It pipeline of antibiotics includes iclaprim, and MTF-001, a preclinical program to design a dihydrofolate reductase inhibitor (DHFRi).
